LENVIMA® (Lenvatinib)

September 16, 2018April 5, 2020 RR FDA Approvals

The FDA on August 16, 2018 approved LENVIMA® capsules for the first-line treatment of patients with unresectable HepatoCellular Carcinoma (HCC). LENVIMA® is a product of Eisai Inc.

LENVIMA® (Lenvatinib)
KEYTRUDA® (Pembrolizumab) and LENVIMA® (Lenvatinib)
LENVIMA® (Lenvatinib) plus KEYTRUDA® (Pembrolizumab)
KEYTRUDA® (Pembrolizumab) in combination with…
FDA Approves LENVIMA® for Unresectable…
LENVIMA® Plus KEYTRUDA® for Advanced Renal…

Top Ad

LENVIMA® (Lenvatinib)

Related Posts:

Bottom Ad

Subscribe